ClinicalTrials.gg
RecruitingNCT07185100WE-CARE-HF-CMRUpdated Apr 1, 2026

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

An observational study in Heart Failure With Preserved Ejection Fraction (HFPEF), Renal Dysfunction and Stage B Heart Failure, sponsored by German Heart Institute. Recruiting at 1 site in Germany. Open to participants aged 40 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by German Heart Institute · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
600
Ages
40 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Renal Insufficiency with a site in Germany — 12 open to participants now, 16 under way, 2 of them phase 3. Renal Insufficiency · Germany.

Planned enrollment
8th of 25
600 · median 428
Started
2025
with 5 others
Observational
25 of 139
7 open now
Primary completion
2026-12
later than 5 of 15 live
Registered
136th of 139
by date

Among the 139 studies in Renal Insufficiency with a site in Germany, this one is the 8th largest by planned enrollment of the 25 observational ones that give a count, is one of 6 that started in 2025, is one of 25 observational ones, reaches primary completion later than 5 of the 15 other live ones, and was the 136th registered.

Renal Insufficiency

1,415 studies on the registry are indexed under Renal Insufficiency; 149 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

12 of the 139 studies in Renal Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 94 Renal Insufficiency studies recruiting now, 49 (52%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Renal Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities/metropol areas in Germany ( > 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas.

The results of the study will be compared with the results from the "HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).

Read the detailed description

The WE-CARE-HF-CMR-study is a cross-sectional, nationwide prospective, community-based observational study to improve the diagnosis of heart failure in urban populations with characteristic risk factors for the occurrence of heart failure using telemedically-supervised mobile diagnostic units. The central diagnostic methods employed in the assessed screening routine comprise a questionnaire-based medical history, laboratory testing and a standardized, non-invasive imaging examination.

Within the framework of the study, 600 subjects aged 40 to 69 years and of male, female or diverse gender, who have characteristic risk factors for the occurrence of asymptomatic heart failure will be examined.

The central diagnostic imaging method of the study is a standardized, needle- as well as stress- and contrast-agent-free CMR exam. The examinations are carried out in mobile MRI diagnostic units at various clinic locations in 5 major cities (> 1.000.000 residents) in Germany. The various clinics were recommended as locations because they offer good infrastructural conditions for setting up the mobile MRI diagnostic units, which are 27 t truck units, and because emergency medical care for the study participants can also be guaranteed. The medical staff of the clinics is not involved in the study. The potential study participants will be informed by the investigators of the DHZC in a video call either in a room rented specifically for this purpose or in an accompanying vehicle of the mobile MRI diagnostic unit. The consent of the study participants is also obtained via telemedicine and in accordance with current legal requirements in Germany. The planned examinations in the mobile diagnostic unit will be carried out exclusively by the staff of the company operating the MRI units on behalf of and under the telemedical supervision of the investigators and the study management of the DHZC, acting as the central unit.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Renal Dysfunction
  • Stage B Heart Failure

Keywords

  • Prevention
  • Heart failure
  • HFpEF
  • Asymptomatic
  • Cardiology
  • Urban area
  • Germany
  • CMR
  • Cardiac Magnetic Resonance
  • HFrEF
  • Diastolic Dysfunction
  • Strain
  • mobile
  • GLS
04

Who can participate

Ages eligible
40 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population from which the groups or cohorts will be selected are asymptomatic adults from the urban areas of Berlin, Cologne, Frankfurt (Main), Hamburg, and Munich with no history of heart failure who have one or more risk factor for developing heart failure. They are either volunteers or referred from local cardiologists.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Asymptomatic subjects with:

  • chronic diabetes mellitus (known/diagnosed and/or antidiabetic medication and/or elevated ) and/or
  • renal impairment (known/diagnosed CKD and/or in laboratory CKD III° or higher) and/or
  • Hypertension (known/diagnosed and/or antihypertensive medication/treatment) and/or
  • Hypercholesterolaemia (known/diagnosed and/or antilipid medication/treatment) and/or
  • Obesity (known/diagnosed and/or > 30 (kg/m²)) and/or
  • Smoker (known/diagnosed and/or current/previous and/or medication/treatment)
  • Age 40-69 years
  • female or male or diverse sex
  • Ability to provide
  • Provision of Informed Consent

Exclusion criteria

Exclusion Criteria:

  • Inability to provide written
  • Diagnosed heart failure or previously detected reduced
  • General MRI exclusion criteria (pacemaker, defibrillator, intracranial aneurysm clips, metallic foreign bodies in the eyes)
  • Any MRI exclusion criteria not listed here, as determined by the MRI laboratory performing the procedure
  • Haemodynamically unstable participants (heart rate \< 45/min, systolic blood pressure \< 90 mmHg)
  • Claustrophobia
  • Sensorineural hearing loss of 30 dB or more and tinnitus
  • Acute mental disorders requiring therapy
  • In the presence of pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients at risk of heart failure

    asymptomatic individuals, residing in urban areas in Germany, between the age of 40 to 69 years without known HF and at least one established cardiovascular risk factor

06

What researchers measure

Primary outcomes

  1. Prevalence of asymptomatic pre-heart failure (stage B) in an urban population

    Asymptomatic pre-heart failure (stage B) is defined as CMR-derived global longitudinal strain (GLS) ≥ -15%

    Time frame: at baseline

Secondary outcomes

  1. Prevalence of chronic kidney disease (CKD)

    CKD is defined as eGFR \< 60%

    Time frame: at baseline

  2. Adherence to therapy

    Assessed using the MARS-10 questionnaire

    Time frame: 1, 5 years and 10 years later

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Peters AE, Clare RM, Chiswell K, Felker GM, Kelsey A, Mentz R, DeVore AD. Echocardiographic Features Beyond Ejection Fraction and Associated Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. Circ Heart Fail. 2023 May;16(5):e010252. doi: 10.1161/CIRCHEARTFAILURE.122.010252. Epub 2023 May 16. PubMed 37192287 ↗
  • Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013 May;6(3):606-19. doi: 10.1161/HHF.0b013e318291329a. Epub 2013 Apr 24. PubMed 23616602 ↗
  • Young KA, Scott CG, Rodeheffer RJ, Chen HH. Progression of Preclinical Heart Failure: A Description of Stage A and B Heart Failure in a Community Population. Circ Cardiovasc Qual Outcomes. 2021 May;14(5):e007216. doi: 10.1161/CIRCOUTCOMES.120.007216. Epub 2021 May 6. PubMed 33951931 ↗
  • Unverzagt S, Meyer G, Mittmann S, Samos FA, Unverzagt M, Prondzinsky R. Improving Treatment Adherence in Heart Failure. Dtsch Arztebl Int. 2016 Jun 24;113(25):423-30. doi: 10.3238/arztebl.2016.0423. PubMed 27397013 ↗
  • Witt UE, Muller ML, Beyer RE, Wieditz J, Salem S, Hashemi D, Chen W, Cvetkovic M, Nolden AC, Doeblin P, Blum M, Thiede G, Huppertz A, Steen H, Remppis BA, Falk V, Friede T, Kelle S. A simplified approach to discriminate between healthy subjects and patients with heart failure using cardiac magnetic resonance myocardial deformation imaging. Eur Heart J Imaging Methods Pract. 2024 Sep 12;2(3):qyae093. doi: 10.1093/ehjimp/qyae093. eCollection 2024 Jul. PubMed 39318449 ↗
  • Young KA, Scott CG, Rodeheffer RJ, Chen HH. Incidence of Preclinical Heart Failure in a Community Population. J Am Heart Assoc. 2022 Aug 2;11(15):e025519. doi: 10.1161/JAHA.122.025519. Epub 2022 Jul 20. PubMed 35862175 ↗
  • NVL Chronische Herzinsuffizienz Langfassung - Version 4.0, 2023
  • Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Nov 17;76(20):2379-2390. doi: 10.1016/j.jacc.2020.09.542. PubMed 33183512 ↗
  • Yang H, Negishi K, Wang Y, Nolan M, Marwick TH. Imaging-Guided Cardioprotective Treatment in a Community Elderly Population of Stage B Heart Failure. JACC Cardiovasc Imaging. 2017 Mar;10(3):217-226. doi: 10.1016/j.jcmg.2016.11.015. PubMed 28279368 ↗
  • Whitmore K, Zhou Z, Chapman N, Huynh Q, Magnussen CG, Sharman JE, Marwick TH. Impact of Patient Visualization of Cardiovascular Images on Modification of Cardiovascular Risk Factors: Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging. 2023 Aug;16(8):1069-1081. doi: 10.1016/j.jcmg.2023.03.007. Epub 2023 May 24. PubMed 37227327 ↗
  • Hood SR, Giazzon AJ, Seamon G, Lane KA, Wang J, Eckert GJ, Tu W, Murray MD. Association Between Medication Adherence and the Outcomes of Heart Failure. Pharmacotherapy. 2018 May;38(5):539-545. doi: 10.1002/phar.2107. Epub 2018 Apr 30. PubMed 29600819 ↗
  • Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, Fonarow GC, Heidenreich P, Ho JE, Hsich E, Ibrahim NE, Jones LM, Khan SS, Khazanie P, Koelling T, Krumholz HM, Khush KK, Lee C, Morris AA, Page RL 2nd, Pandey A, Piano MR, Stehlik J, Stevenson LW, Teerlink JR, Vaduganathan M, Ziaeian B; Writing Committee Members. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26. No abstract available. PubMed 37797885 ↗
  • Haji K, Huynh Q, Wong C, Stewart S, Carrington M, Marwick TH. Improving the Characterization of Stage A and B Heart Failure by Adding Global Longitudinal Strain. JACC Cardiovasc Imaging. 2022 Aug;15(8):1380-1387. doi: 10.1016/j.jcmg.2022.03.007. Epub 2022 May 11. PubMed 35926896 ↗
  • Potter E, Stephenson G, Harris J, Wright L, Marwick TH. Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients. Eur J Heart Fail. 2022 Apr;24(4):620-630. doi: 10.1002/ejhf.2428. Epub 2022 Jan 27. PubMed 35014128 ↗
  • Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS; QUALIFY Investigators. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017 Nov;19(11):1414-1423. doi: 10.1002/ejhf.887. Epub 2017 Apr 30. PubMed 28463464 ↗
  • Li JJ, Thiede G, Gotze C, Exarchos V, Meuwly C, Werhahn SM, Beyer RE, Muller ML, Bigvava T, Stehning C, Remppis BA, Wieditz J, Sack S, Heer T, Sroka M, Nagel E, Hays AG, Duvigneau G, Blankenberg S, Steen H, Frey N, Baldus S, Seuthe K, Lorbach R, Rodicker F, Scharf S, Hilgendorf I, Landmesser U, Friede T, Falk V, Doeblin P, Kelle S. Design and rationale of the WE-CARE-HF-CMR trial: Cardiorenal care on wheels for asymptomatic heart failure patients (NCT07185100). J Cardiovasc Magn Reson. 2026 May 15;28(2):102745. doi: 10.1016/j.jocmr.2026.102745. Online ahead of print. PubMed 42142740 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 22, 2025
StartActual
Sep 13, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2036
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07185100
Lead sponsor
German Heart Institute
Collaborators
AstraZeneca, Philips Healthcare, Deutsches Herzzentrum der Charité, Berlin, German Heart Center Foundation, Nationale Herzallianz (NHA), Deutsche Herzstiftung
Responsible party
Sebastian Kelle (Dr. Sebastian Kelle (MD), German Heart Institute) — Principal investigator
First posted
Sep 22, 2025
Start date
Sep 13, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
Apr 1, 2026

Study contacts

Prof. Dr. Sebastian Kelle
Contact
sebastian.kelle@dhzc-charite.de
+493045931182
Dr. Gisela Thiede
Contact
gisela.thiede@dhzc-charite.de
+4915209192843
Sebastian Kelle, Prof. Dr.
principal investigator · Deutsches Herzzentrum der Charité

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion